Cognition Therapeutics presented an analysis from the Phase 2 COG1201 SHIMMER study of zervimesine (CT1812) in dementia with Lewy bodies at the AD/PD conference.

Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 COG1201 SHIMMER study (NCT05225415) of zervimesine (CT1812) in dementia with Lewy bodies (DLB) at the AD/PD™ 2026 Alzheimer's & Parkinson's Diseases Conference. The conference is being conducted March 17-21, 2026 in Copenhagen, Denmark. The analysis focuses on Zervimesine's treatment effects on the behavioral and psychiatric symptoms most commonly associated with DLB.

"In the Phase 2 'SHIMMER' study, we saw a treatment effect across neuropsychiatric, cognitive, motor, and global function domains with zervimesine treatment compared to placebo," explained Anthony Caggiano, MD, PhD, Cognition's CMO. "This effect was particularly robust against DLB's behavioral and psychiatric symptoms, which have been identified as important to patients and care partners. We're presenting a breakdown of zervimesine's effect relative to placebo on the components of the neuropsychiatric index (NPI), which was employed in the Phase 2 study."

Zervimesine treatment resulted in an 86% slowing of decline on NPI-12 vs placebo in that Phase 2 study. This slowing of decline reflects zervimesine's unique disease-modifying mechanism of action. Acute treatments for psychosis may improve one symptom but will not delay progression of the disease. Based on our clinical data, we believe zervimesine has the potential to slow DLB progression and reduce the progression of its associated neuropsychiatric symptoms.

Its unique mechanism should also allow zervimesine to be used in DLB patients who cannot tolerate traditional antipsychotics and benzodiazepines. Some medications, such as haloperidol, are contraindicated in patients with DLB, who may exhibit severe parkinsonism, sedation, and immobility in response. Unlike traditional antipsychotics, zervimesine demonstrated a directionally favorable impact on cognitive fluctuations, memory, movement symptoms, and activities of daily living.

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon
COMTEX_478962012/2227/2026-05-11T22:18:05